Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company utilizes a proprietary induced pluripotent stem cell (iPSC) platform to create off-the-shelf, multiplexed-engineered T-cell and natural killer (NK) cell product candidates. By leveraging clonal master iPSC lines, Fate Therapeutics aims to provide scalable, accessible, and standardized cellular therapies that can be administered without the need for complex, patient-specific manufacturing processes. Their pipeline focuses on addressing significant unmet medical needs in oncology and autoimmune diseases.